UCB Past Earnings Performance
Past criteria checks 2/6
UCB has been growing earnings at an average annual rate of 1.6%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 5.8% per year. UCB's return on equity is 4.6%, and it has net margins of 7.7%.
Key information
1.6%
Earnings growth rate
1.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 5.8% |
| Return on equity | 4.6% |
| Net Margin | 7.7% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How UCB makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 5,447 | 420 | 1,714 | 1,670 |
| 30 Jun 22 | 5,854 | 887 | 1,695 | 1,674 |
| 31 Mar 22 | 5,816 | 971 | 1,625 | 1,652 |
| 31 Dec 21 | 5,777 | 1,055 | 1,554 | 1,629 |
| 30 Sep 21 | 5,647 | 996 | 1,506 | 1,631 |
| 30 Jun 21 | 5,517 | 936 | 1,458 | 1,633 |
| 31 Mar 21 | 5,432 | 834 | 1,438 | 1,601 |
| 31 Dec 20 | 5,347 | 732 | 1,417 | 1,569 |
| 30 Jun 20 | 5,198 | 743 | 1,368 | 1,393 |
| 31 Mar 20 | 5,056 | 767 | 1,336 | 1,333 |
| 31 Dec 19 | 4,913 | 790 | 1,303 | 1,272 |
| 30 Jun 19 | 4,686 | 652 | 1,212 | 1,229 |
| 31 Mar 19 | 4,659 | 722 | 1,178 | 1,195 |
| 31 Dec 18 | 4,632 | 792 | 1,144 | 1,161 |
| 30 Jun 18 | 4,569 | 872 | 1,105 | 1,083 |
| 31 Mar 18 | 4,522 | 812 | 1,119 | 1,070 |
| 31 Dec 17 | 4,474 | 752 | 1,132 | 1,057 |
| 30 Sep 17 | 4,400 | 708 | 1,138 | 1,047 |
| 30 Jun 17 | 4,325 | 664 | 1,144 | 1,036 |
| 31 Mar 17 | 4,236 | 604 | 1,133 | 1,028 |
| 31 Dec 16 | 4,147 | 543 | 1,122 | 1,020 |
| 30 Sep 16 | 4,051 | 439 | 1,111 | 1,022 |
| 30 Jun 16 | 3,955 | 334 | 1,099 | 1,023 |
Quality Earnings: UCB N has high quality earnings.
Growing Profit Margin: UCB N's current net profit margins (7.7%) are lower than last year (18.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UCB N's earnings have grown by 1.6% per year over the past 5 years.
Accelerating Growth: UCB N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: UCB N had negative earnings growth (-60.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.1%).
Return on Equity
High ROE: UCB N's Return on Equity (4.6%) is considered low.